Editor’s note: The video recording is embedded below.
The pandemic caused by the novel coronavirus has shut down countries around the world. One of society’s biggest hopes is that treatments or even vaccines can be developed.
Join STAT for a three-part digital event series starting today, covering the race for new medicines that will impact Covid-19. The audience will be joined by executives from companies leading the way in developing treatments, who will come prepared to answer tough questions. They’ll discuss current findings, clinical trials, and efforts to expedite approvals as we face this global pandemic.
This series will take place on Zoom, an interactive video conference platform where attendees will be able to not only see the discussions live, but also participate by asking questions during the event. Access to each event is free, but access to the Zoom platform is limited to the first 1,000 attendees. Any additional attendees will be able to watch the conversation below in real time via a live stream.
More information about today’s chat:
Part 1: Antibody drugs that target the coronavirus
April 8, 2020 at 1 p.m. EST
- Sponsor Introduction: Stephen J. Ubl, president and chief executive officer, PhRMA
- George Yancopoulos, co-founder, president, and chief scientific officer, Regeneron
- Matt Herper, senior writer, medicine, and editorial director of events, STAT